TABLE 1.
Demographics and baseline characteristics (intent-to-treat population)
| Subjects | 198 |
| Age years | 60.7±9.5 |
| Male | 104 (53) |
| Ethnicity | |
| White | 179 (90) |
| African-American or African heritage | 19 (10) |
| Current smoker at screening | 127 (64) |
| Smoking pack-years | 52.2±23.5 |
| Pre-salbutamol FEV1 L | 1.37±0.50 |
| Post-salbutamol FEV1 L | 1.52±0.49 |
| Post-salbutamol FEV1/FVC | 51.3±9.79 |
| Post-salbutamol FEV1 % pred | 50.5±10.5 |
| Inspiratory capacity L | 2.13±0.72 |
| Functional residual capacity L | 4.67±1.03 |
| Functional residual capacity % pred | 147±22.9 |
| Residual volume L | 3.88±0.92 |
| Total lung capacity L | 6.79±1.40 |
| Reversible to salbutamol# | 73 (37) |
| ICS user | 55 (28) |
| GOLD grade | |
| 2 | 106 (54) |
| 3 | 92 (46) |
| GOLD category using mMRC criteria | |
| B | 94 (47) |
| D | 104 (53) |
| mMRC Dyspnoea scale | 2.5±0.6 |
Data are presented as n, mean±sd or n (%). FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroid; GOLD: Global initiative for Chronic Obstructive Lung Disease; mMRC: modified Medical Research Council. #: defined as an increase in FEV1 of ≥12% and ≥200 mL following administration of salbutamol.